Form D · Biotechnology

Neurana Pharmaceuticals, Inc.

San Diego, CA · CIK 0001699458

Offering snapshot reported Feb 26, 2020 · SEC filing

Reported sold: $41.9M
Investors reported: 14
Minimum accepted: $0
First sale: May 3, 2018

Fundraising history

Reported sold

Dates are filing dates, not cash receipt dates. Decreases are reported revisions, not evidence of withdrawals. Separate offering histories are not added together.

What changed?

Latest filing versus its linked predecessor, where available.

Reported sold$29,888,249 → $41,888,250

Filing history

Scroll to see all columns →

Filed	Filing type	Reported sold	Change vs linked filing	Investors	Source
Feb 26, 2020	Amendment	$41,888,250	$12,000,001vs May 14, 2018	14	SEC filing
May 14, 2018	Amendment	$3,818,750	$2,768,750vs Mar 10, 2017	8	SEC filing
May 14, 2018	Initial	$29,888,249	No comparison	14	SEC filing
Mar 10, 2017	Initial	$1,050,000	No comparison	3	SEC filing

Offering details

Securities: Equity
Exemptions: 06b
Duration over one year: Yes
Business combination: No

Sales commissions: $0
Finders' fees: $0
Form D file number: 021-312331

Source: Form D, filed Feb 26, 2020. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
Name	Reported role
Daniel Becker	Director
Judy Caron	Executive
Brian Dorsey	Director
David F. Hale	Director
David Kabakoff	Director
Randall Kaye, M.D.	Executive
Jeffrey Raser	Director, Executive
Joshua Richardson	Director
Kathleen D. Scott	Executive
Craig Thompson	Director, Executive
Alex Zisson	Director

Issuer details

Industry: Biotechnology (See others in industry)

Address:

4370 La Jolla Village Drive Suite 860
San Diego, CA, 92122